Filter the drugs by the phase of research, how they help and the responsive mutations.
Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene. Browse the
database of
drugs treating specific mutations compiled by the AIM tool.
| Drug | Marketed as | Description | Phase of research | How it helps |
|---|---|---|---|---|
| OligoG | Decreases the thickness of mucus in the lungs |
Phase Two Clinical Trial | Mucociliary Clearance | |
| Ouabain | plant-derived toxic substrance, CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| PAP | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| PEMA | CFTR corrector and potentiator |
Pre-clinical | Restore CFTR Function | |
| PFDN2 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| POL6014 | Neutrophil elastase inhibitor |
Phase One Clinical Trial | Anti-Inflammatory | |
| RDR1 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| RDR3 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| SAPK substrate protein 1 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| SPX-101 | Blocks the function of sodium channel in lungs, maintaining fluid to improve mucus clearance |
Phase Two Clinical Trial | Mucociliary Clearance |
